Nine-month-old KJ Muldoon, diagnosed with CPSI deficiency at birth, is the first known patient treated with CRISPR gene editing therapy, having spent over 300 days in the hospital. His genetic disorder prevented the breakdown of ammonia, leading to dangerous health risks. Traditional treatments involve severe dietary restrictions and potential liver transplants. Researchers from CHOP and the University of Pennsylvania utilized CRISPR technology to develop a personalized therapy for KJ, targeting his genetic mutation to correct his liver cells. His journey represents a groundbreaking achievement in gene therapy for rare genetic conditions, giving hope to similar future treatments.
KJ's parents expressed immense gratitude for the medical team that developed the CRISPR therapy, emphasizing the transformative impact it had on their son’s health journey.
This groundbreaking CRISPR treatment not only saved KJ's life but also opens the door to future therapies for children suffering from rare genetic disorders.
Collection
[
|
...
]